StreetInsider.com News Articles

Kalaris reports positive TH103 Phase 1a data in neovascular AMD

Fri, 17 Jul 2026 07:00:16 -0400

Kalaris Therapeutics (Nasdaq: KLRS) reported positive data from expanded cohorts in its Phase 1a single ascending dose trial of TH103 in neovascular age-related macular degeneration (AMD), according to a company statement.

The expanded dataset now includes 17 treatment-naive patients and 3 treatment-experienced patients, all of whom completed six months of follow-up. The efficacy analysis of treatment-naive patients showed structural and functional improvements consistent with previously reported findings.

Pharmacokinetic data showed TH103 plasma levels with 27- to 53-fold lower peak concentrations compared to current leading anti-VEGF agents on a molar equivalence basis, which the company said suggests greater intraocular retention.

Time-to-retreatment results among treatment-naive

Kalaris reports positive TH103 Phase 1a data in neovascular AMD

Fri, 17 Jul 2026 07:00:16 -0400

Time-to-retreatment results among treatment-naive

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Fri, 17 Jul 2026 07:00:00 -0400

Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts

Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with preliminary data on track for 1H 2027

BERKELEY HEIGHTS, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced positive additional data from its Phase 1a single ascending dose (SAD) trial of TH103 in neovascular age-related macular degeneration (AMD). Data from the

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Fri, 17 Jul 2026 07:00:00 -0400

Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts

Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with preliminary data on track for 1H 2027

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Fri, 17 Jul 2026 07:00:00 -0400

Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts

Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with preliminary data on track for 1H 2027

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Fri, 17 Jul 2026 07:00:00 -0400

Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts

Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with preliminary data on track for 1H 2027

Kalaris Therapeutics names Laurie Keating to its board